MEET THE PRECISEU ADVISORY BOARD

6/05/2025

Eleven experts. One mission: accelerating the future of Personalised Healthcare in Europe.

The PRECISEU, consortium is proud to announce the creation of our Advisory Board (AB) — a team of 11 distinguished experts from across Europe and the USA who will play a vital role in steering our project toward greater impact and long-term sustainability.

What is PRECISEU?

The general purpose of PRECISEU, the Horizon-Europe funded Regional Innovation Valley on Personalised Medicine, is connecting innovation ecosystems across Europe to efficiently advance towards a truly personalised healthcare. PRECISEU contributes to transferring practices and solutions across the 12 regions participating in the consortium, and scaling up deep-tech healthcare innovations based on advanced therapies medicinal products and health data across Europe.

With a core of coordination and support activities among the 25 partners of he project, and a large cascade funding initiative to support Innovations advance from TRL 6 to 8, the project works to reduce fragmentation and inequalities and accelerate Personalised Medicine in Europe.

Meet our Advisory Board members

The distinguished AB comprises highly qualified professionals with broad strategic views and extensive experience in impactful research, innovation and exploitation of results in Personalised Medicine, with a strong focus on Advanced Therapies, Health Data and Market Access. The AB will act as a strategic think-tank supporting the project’s successful implementation and evolution.

The eleven experts have been carefully selected to ensure a diverse balance in terms of expertise, gender, and geographical representation.

Wolfgang Ballensiefen, Germany

German Aerospace Center – Coordinator of EP Permed

Chair of PRECISEU AB

Focus: Personalised Medicine

 

Aneta Tyszkiewicz, Poland

EPFIA, European Federation of Pharmaceutical Industries and Associations – Associate Director, Digital & Data for the Science Policy and Regulatory Affairs team

Focus: Industry

 

Edward Abrahams, USA

Personalized Medicine Coalition – President of PM Coalition

Focus: Personalised Medicine

 

Annalisa Scopinaro, Italy

UNIAMO, Italian Federation of Rare Diseases – President of UNIAMO

Focus: Rare diseases and patient advocacy

 

Josep Samitier, Spain

Institute for Bioengineering of Catalonia and Catalan Association of Research Centres – Director of  IBEC and President of ACER

Focus: Research organisations

 

Nuria Queralt Rosinach, Netherlands

Leiden University Medical Center- Researcher in Biomedical Informatics and FAIR data

Focus: Health Data

   

Toni Cathomen, Germany

University hospital Freibrug – Director for Institute for Transfusion Medicine and Gene Therapy

Focus: Advanced Therapies

 

Sonata Jarmalaitė, Lithuania

Vilnius University and the National Cancer Institute – Professor of Genetics at VU and Deputy Director for Research and development at the NCI

Focus: Molecular mechanisms of cancer

 

Gisela Helenius, Sweden

ATMP Sweden – Head of Unit ATMP Center

Focus: National Advanced Therapies strategies

 

 

Ebba Hallersjö Hult, Sweden

Stockholm School of Economics – Head of  Vision Zero Cancer and Test Bed Sweden

Focus: Impact of Personalised Medicine

 

Gemma Valeta, Spain

SALUT, Catalan Health Service (CatSalut) – Manager of Personalized and Precision Medicine area

Focus: Policymaking for Personalized Medicine

 

Working closely with the project’s Coordination team and the Work Package leads, the AB will provide valuable insights on the challenges of Personalised Medicine implementation in healthcare across Europe, and recommendations on enhancing the impact and sustainability of project activities.

Throughout the project, five General Assembly Meetings (physical and online) are planned, and in each of them the consortium will invite AB members to receive their guidance and insights. Additionally, the AB members will serve as  Ambassadors, actively supporting the dissemination of main project initiatives and results across Europe. Their fresh, independent perspectives will help ensure the relevance, impact and broader connections of PRECISEU, and will ensure that the project’s innovative and impactful results contribute to transforming healthcare.